eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

  • Novel lipid nanoparticles for mRNA delivery will enhance thermostability, biodegradability and safety and pave the way for new off-the-shelf therapies

eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA immunotherapies for the treatment of cancer and infectious diseases, announces a collaboration and license agreement with Ghent University.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH